Chronic Gout Market to Register Growth at an Extraordinary CAGR by 2032 | DelveInsight

Chronic Gout Market to Register Growth at an Extraordinary CAGR by 2032 | DelveInsight

The Chronic Gout Market is expected to show positive growth in the forecast period (2022–2032) due to the development of well-designed, randomized, controlled non-crossover trials with potential benefits. Moreover, the shortfall of approved therapy might provide suitable space for emerging therapies.

DelveInsight’s Chronic Gout Market Insights report includes a comprehensive understanding of current treatment practices, Chronic Gout emerging drugs, Chronic Gout market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].

Key takeaways from the Chronic Gout Market Research Report

  • According to DelveInsight estimates, the Chronic Gout market size was approximately USD 2,613.1 million in 2020.
  • As per analysis, the total Chronic Gout prevalent cases were found to be more than 2 million in the 7MM in 2018.
  • Leading Chronic Pain Companies such as Jiangsu Atom Bioscience and Pharmaceutical, Arthrosi Therapuetics, Teijin Limited, Selecta Biosciences Inc, Shanton Pharma, and many others are developing novel Chronic Gout drugs that can be available in the Chronic Gout market in the upcoming years.
  • The promising Chronic Gout therapies in the pipeline include ABP 671, AR-882, TMX-049, Pegadricase-SVP, SAP 001, and many others.

Know which therapies are expected to grab major Chronic Gout Market Share @ Chronic Gout Market Report

Chronic Gout Overview

Gout is a chronic disease characterized by the deposition of monosodium urate (MSU) crystals. Gout often manifests as an acute, self-limiting inflammatory monoarthritis of the lower limb joints. Chronic Gout is defined by long-term joint inflammation that causes joint discomfort at rest and during activity. Among the most common Chronic Gout causes is hyperuricemia. Higher serum urate levels are associated with an increased risk of gout flare-ups and more frequent flare-ups over time.

The most common Chronic Gout symptom is intense joint pain, followed by discomfort, inflammation, and redness. In the setting of acute inflammatory arthritis, laboratory confirmation of synovial fluid MSU is required for a definitive Chronic Gout diagnosis. As a result, a systematic review comparing the accuracy of tests used to diagnose Chronic Gout, such as physical findings, serum UA, ultrasound (US), plain radiography, and dual-energy computed tomography (DECT), to synovial fluid UA can be used to inform clinical decision-making for patients and providers, as well as improve the quality of care for gout patients in the primary and acute care setting.

Chronic Gout Epidemiology Segmentation in the 7MM

  • Total Chronic Gout Prevalent cases
  • Total Chronic Gout Prevalent cases
  • Chronic Gout Gender-specific Prevalent Cases
  • Total Chronic Gout Prevalent Cases of Chronic Gout based on Risk Factors

For further information of this report to understand which factors are driving Chronic Gout epidemiology trends @ Chronic Gout Epidemiological Insights

Chronic Gout Treatment Market

Gout treatment focuses on two areas: reducing gout inflammation and pain associated with gout and preventing gout complications by lowering blood urate levels. Gout management encompasses flare management, chronic gout management, flare avoidance, and comorbidity control. Newer Chronic Gout drugs in the pharmacological arsenal are proving effective and are supplementing previous ones. Other significant aspects of its care include patient education, dietary and lifestyle modifications, and the discontinuation of hyperuricemic drugs.

Chronic Gout Pipeline Therapies and Key Companies

  • ABP 671: Jiangsu Atom Bioscience and Pharmaceutical
  • AR-882 Arthrosi Therapuetics
  • TMX-049 Teijin Limited
  • Pegadricase-SVP: Selecta Biosciences, Inc.
  • SAP 001: Shanton Pharma

Learn more about the Chronic Gout therapies in clinical trials @ Drugs for Chronic Gout Treatment

Chronic Gout Market Dynamics

The Chronic Gout market is shifting positively as the gout incidence and prevalence have risen dramatically in recent decades. Gout treatment in individuals with concomitant metabolic syndrome and comorbid conditions such as renal impairment was challenging until recently due to restricted therapeutic choices in the Chronic Gout market. However, great improvement has been achieved in recent years, with the advent of novel drugs for Chronic Gout, such as febuxostat and pegloticase.

Many other drugs with a rational mechanism of action are in development and will most likely be launch in the coming years in the Chronic Gout market. Thus, a new era in the area of gout has begun which will further drive the Chronic Gout market forward. At present, Teijin Pharma, Horizon Therapeutics, Sanwa Kagaku Kenkyusho Co. Ltd., and others are actively working in the Chronic Gout market towards the development of potential therapy to overcome the unmet medical needs of the currently used therapeutics.

Chronic Gout Market Factors

However, certain Chronic Gout market factors are hindering the growth of the Chronic Gout market. There is a pervasive dearth of information and understanding about gout care among both patients and doctors. Although gout is treatable, a lack of understanding leads to underdiagnoses and undertreatment, particularly in individuals who do not meet the ‘stereotypical gout’ profile (for example, younger patients). In addition, factors such as inadequate monitoring and care and stigma related to Chronic Gout are also acting as a barrier to the Chronic Gout market growth.

Scope of the Chronic Gout Market Research Report

  • Study Period- 2019-2032
  • Forecast Period- 2022-2032
  • Key Chronic Gout Companies- Jiangsu Atom Bioscience and Pharmaceutical, Arthrosi Therapuetics, Teijin Limited, Selecta Biosciences Inc, Shanton Pharma, and many others.
  • Key Chronic Gout therapies- ABP 671, AR-882, TMX-049, Pegadricase-SVP, SAP 001, and many others.
  • Chronic Gout Therapeutic Assessment- Current marketed and emerging therapies
  • Chronic Gout Market Dynamics- Chronic Gout Market Drivers and Barriers
  • Competitive Intelligence Analysis- SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Chronic Gout Market Access and Reimbursement

Discover more about Chronic Gout medications in development @ Chronic Gout Clinical Trials

Table of Content

1. Key Insights

2. Executive Summary of Chronic Gout

3. Competitive Intelligence Analysis for Chronic Gout

4. Chronic Gout: Market Overview at a Glance

5. Chronic Gout: Disease Background and Overview

6. Patient Journey

7. Chronic Gout Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Chronic Gout Unmet Needs

10. Key Endpoints of Chronic Gout Treatment

11. Chronic Gout Marketed Products

12. Chronic Gout Emerging Therapies

13. Chronic Gout: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Chronic Gout

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Get in touch with our Business Executive @ Chronic Gout Market Size


About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States